Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management—summary of updated NICE guidance
BMJ 2024; 387 doi: https://doi.org/10.1136/bmj.q2452 (Published 27 November 2024) Cite this as: BMJ 2024;387:q2452- Aye Paing, technical analyst1,
- Laura Elliff-O’Shea, technical adviser1,
- Lisa Boardman, guideline topic lead1,
- David Turner, clinical associate professor and honorary consultant microbiologist2,
- Linda Glennie, lay member3
- on behalf of the Guideline Committee
- 1National Institute for Health and Care Excellence, London, UK
- 2Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK
- 3Meningitis Research Foundation, The Pithay, Bristol, UK (retired)
- Correspondence to: Aye Paing aye.paing{at}nice.org.uk
What you need to know
Identification of red flag combinations of symptoms and signs should raise the index of suspicion of bacterial meningitis or meningococcal disease
A senior clinical decision maker should perform an initial assessment and ensure that antibiotics start within 1 hour of the person arriving at hospital
Review people who have had bacterial meningitis or meningococcal disease within 4-6 weeks after discharge from hospital
Bacterial meningitis and meningococcal disease are uncommon but life-threatening conditions. Early recognition is important but difficult because of the non-specific ways in which individuals present. The National Institute for Health and Care Excellence (NICE) initially published guidance on the conditions in 2010 and, after a surveillance review in 2018, updated it following changes in guideline development methodology and to reflect recent developments in vaccination.1 The 2024 guidance also extends the population of the original guideline from children only to including recommendations for adults.1
The term “bacterial meningitis” includes meningococcal meningitis without meningococcal sepsis and meningitis caused by other bacteria, while the term “meningococcal disease” includes meningococcal sepsis with or without meningococcal meningitis. Evidence for the two conditions was reviewed separately but considered in parallel. Whether separate recommendations were needed for each condition was decided based on the evidence and Guideline Committee’s experience. In this article, we summarise selected recommendations related to early recognition of these conditions, timing of investigations, initiating antibiotic therapy, and follow-up.
Recommendations
NICE recommendations are based on systematic reviews of best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on the Guideline Committee’s experience and opinion of what constitutes good practice. Evidence levels for the recommendations are given in italic in square brackets.
GRADE Working Group grades of evidence
High certainty—we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty—we …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.